Nears completion of ONWARD™ Phase 3 pivotal trial of AD04 for the treatment of Alcohol Use Disorder; on track to report Phase 3 results in the current quarter
Ended first quarter with cash and cash equivalents of $12.7 million
Read more at globenewswire.com